Fungal persister cells: The basis for recalcitrant infections?
Open accessThe DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Persister cells are a small subpopulation within fungal biofilms that are highly resistant to high concentrations of antifungals and therefore most likely contribute to the resistance and recalcitrance of biofilm infections. Moreover, this subpopulation is defined as a nongrowing, phenotypic variant of wild-type cells that can survive high doses of antifungals. There are high degrees of heterogeneity and plasticity associated with biofilm formation, resulting in a strong variation in the amount of persister cells. The fraction of these cells in fungal biofilms also appear to be dependent on the type of substrate. The cells can be observed immediately after their adhesion to that substrate, which makes up the initial step of biofilm formation. Thus far, persister cells have primarily been studied in Candida spp. These fungi are the fourth most common cause of nosocomial systemic infections in the United States, with C. albicans being the most prevalent species. Remarkably, persisters exhibit characteristics of a dormant state similar to what is observed in cells deprived of glucose. This dormant state, together with attachment to a substrate, appears to provide the cells with characteristics that help them overcome the challenges with fungicidal drugs such as amphotericin B (AmB). AmB is known to induce apoptosis, and persister cells are able to cope with the increase in reactive oxygen species (ROS) by activating stress response pathways and the accumulation of high amounts of glycogen and trehalose-two known stress-protecting molecules. In this review, we discuss the molecular pathways that are involved in persister cell formation in fungal species and highlight that the eradication of persister cells could lead to a strong reduction of treatment failure in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Whereas tolerance is generally due to substantial subpopulations of cells (5-90%) that grow in drug, antifungal heteroresistance or persistence involve rare cells (generally <<1%) that transiently survive high concentrations of antifungal drugs14.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“biofilms are known to hinder the penetration of antifungal drugs and host immune effectors and also trigger the formation of Candida persister cells, leading to poor clinical outcomes [52,53].”
From Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs (2020) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is difficult to detect persisters in planktonic cells, which is different from bacteria [12,16].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One possible explanation is antifungal persistence, given its ability to survive lethal drug exposure without an increase of resistance level [12].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Fungal persisters are dormant variants of wild-type cells that are tolerant to antifungal drugs, surviving high dosage of antifungals that exceed the minimal inhibitory concentration (MIC) [12,16].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Maisonneuve, E., Castro-Camargo, M., & Gerdes, K. (2013) · Cell · doi:10.1016/j.cell.2013.07.048 · Cited by 438
RetractedIn situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Candida albicans pathogenicity mechanisms
Mayer, F. L., Wilson, D., & Hube, B. (2013) · Virulence · doi:10.4161/viru.22913 · Cited by 1,848
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION
Bigger, J. (1944) · The Lancet · doi:10.1016/s0140-6736(00)74210-3 · Cited by 1,178
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Bacterial Persisters and Infection: Past, Present, and Progressing
Gollan, B., Grabe, G., Michaux, C., & Helaine, S. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115650 · Cited by 280
Candida albicans biofilms and polymicrobial interactions
Ponde, N. O., Lortal, L., Ramage, G., Naglik, J. R., & Richardson, J. P. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1843400 · Cited by 281
“Patients with long-term oral carriage of C. albicans have a higher incidence of persister cells (LaFleur et al. 2010), suggesting that persister cells may be relevant in the context of continual colonisation or recurrent infections in vivo (Wuyts et al. 2018).”
BackgroundCandidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
“18,19 The development of IC induces a response from all arms of the immune system.”
Evolutionary causes and consequences of bacterial antibiotic persistence
Bakkeren, E., Diard, M., & Hardt, W.-D. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0378-z · Cited by 224
Metadata
- Authors
- Wuyts, J., Van Dijck, P., & Holtappels, M.
- Affiliations
- VIB-KU Leuven Center for Microbiology (BE)
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-10-18
- Volume
- 14
- Issue
- 10
- Pages
- e1007301
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC6193731
- OpenAlex
- W2897950718
- Cited by
- 136
- References
- 87
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 19 · 2020: 19 · 2019: 10
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Belgian Federal Science Policy Office
- KU Leuven (C14/17/063)
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- fungal biofilms, antifungal resistance, recalcitrant infection, Candida albicans, Candida, amphotericin B resistance, dormancy, reactive oxygen species, stress response pathways, trehalose, glycogen, nosocomial fungal infections, treatment failure
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Cross Infection, Humans, Biofilms, Drug Resistance, Multiple, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.